Skip to main content
Median Diagnostics Inc. logo

Median Diagnostics Inc. — Investor Relations & Filings

Ticker · 233250 ISIN · KR7233250000 KO Manufacturing
Open in API
Filings indexed 118 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country KR South Korea
Listing KO 233250

About Median Diagnostics Inc.

https://www.mediandiagnostics.com/en

Median Diagnostics Inc. specializes in the development, manufacturing, and supply of in-vitro diagnostic products for animal diseases. The company provides a comprehensive portfolio of diagnostic solutions, including ELISA and PCR kits, rapid tests, and standard reagents. It also produces essential raw materials such as monoclonal antibodies and antigens. A primary focus is on offering 'Total Diagnostic Systems' for high-consequence animal diseases, including African Swine Fever (ASF), Foot-and-Mouth Disease (FMD), High Pathogenicity Avian Influenza (HPAI), Porcine Epidemic Diarrhea (PED), and Bovine Viral Diarrhea (BVD). The company also supplies raw materials for human disease diagnostic applications.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Regulatory Filings Classification · 78% confidence The document is a notice (in Korean) announcing the scheduling and details of an upcoming investor relations (IR) presentation/event, including date, time, audience, venue, and agenda. It does not contain the presentation content itself or any financial statements, nor is it a formal earnings release or report. There is no specific category for an IR event announcement, so it falls under the general “Regulatory Filings” fallback category.
2026-05-18 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is the official notification of resolutions and voting outcomes from the company’s 2026 Annual General Meeting, detailing approval of financial statements, dividend resolutions, agenda votes with passage rates, and related report items. This corresponds to a Declaration of Voting Results at a shareholder meeting.
2026-03-26 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Median Diagnostic' (주식회사 메디안디노스틱) for the fiscal year ending December 31, 2025. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes to the financial statements. As it contains the full set of audited financial statements for a specific fiscal period, it is classified as an Audit Report (AR). FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) dated 2026.03.18. It provides the audit opinion, key financial data, and the name of the accounting firm (태성회계법인). While it contains financial data, it is a standalone regulatory disclosure regarding the submission of the audit report rather than the full annual report (10-K) or a simple announcement of publication (RPA). Given the specific nature of audit report submissions in the Korean regulatory context, it fits best under the Audit Report (AR) category. FY 2025
2026-03-18 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Median Diagnostics. It contains the meeting agenda, details on board activities, and financial statements (balance sheet, income statement, etc.) intended for shareholder review prior to the meeting. This type of document is classified as a Proxy Solicitation & Information Statement (PSI) because it provides shareholders with the necessary information to vote on agenda items at the upcoming general meeting.
2026-03-12 Korean
주주총회소집결의
AGM Information Classification · 97% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집 결의) issued by Median Diagnostics. It outlines the date, location, and agenda items (financial statement approval, articles of incorporation changes, and director compensation). This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of upcoming meeting details and agenda items, fitting the definition of PSI.
2026-02-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.